Un­de­terred by ex­ec ex­o­dus, Im­muno­core nabs $100M cash to co-de­vel­op pre­clin­i­cal as­set with Roche

De­spite its re­cent ex­ec­u­tive ex­o­dus, can­cer biotech Im­muno­core’s ap­petite for part­ner­ship deals re­mains re­lent­less. The Ox­ford Uni­ver­si­ty spin­out is now set to test a pre­clin­i­cal …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER